BioAge Labs, Inc. (BIOA)
| Market Cap | 697.91M +399.2% |
| Revenue (ttm) | 10.32M +611.0% |
| Net Income | -89.93M |
| EPS | -2.39 |
| Shares Out | 44.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 376,314 |
| Open | 16.87 |
| Previous Close | 17.02 |
| Day's Range | 15.68 - 17.16 |
| 52-Week Range | 4.07 - 24.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 49.50 (+215.29%) |
| Earnings Date | May 8, 2026 |
About BIOA
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for BIOA stock is "Buy." The 12-month stock price target is $49.5, which is an increase of 215.29% from the latest price.
News
BioAge Labs Transcript: Jefferies Global Healthcare Conference 2026
BGE-102, a novel NLRP3 inhibitor, showed strong biomarker reductions and excellent tolerability in phase I, with phase II cardiovascular and DME trials underway. The program is well-funded, with key data and potential phase III enablement expected by year-end.
BioAge Labs initiated with a Buy at Roth Capital
Roth Capital analyst Adam Walsh initiated coverage of BioAge Labs (BIOA) with a Buy rating and $36 price target The firm believes the company’s lead asset BGE-102, am NLRP3 program…
BioAge Labs initiated with a Buy at BTIG
BTIG initiated coverage of BioAge Labs (BIOA) with a Buy rating and $40 price target BioAge is a clinical-stage biopharmaceutical company focused on treating disease related to human aging, the…
BioAge Labs Transcript: R&D Day 2026
BGE-102, an oral NLRP3 inhibitor, showed robust Phase I efficacy and safety, with up to 86% CRP reduction and strong CNS/retinal penetration. Phase II trials in cardiovascular risk and diabetic macular edema are underway, supported by a strong cash position and expert validation of the anti-inflammatory strategy.
BioAge Labs Slides: FY 2026
BioAge Labs has posted slides in relation to its FY 2026 quarterly earnings report, which was published on May 8, 2026.
BioAge Labs reports Q1 EPS (52c), consensus (63c)
Reports Q1 revenue $2.77M, consensus $1.08M. “The positive topline Phase 1 data we reported for BGE-102 in April reinforce our conviction that we have a potential best-in-class NLRP3 inhibitor: a…
BioAge Labs Quarterly report: Q1 2026
BioAge Labs has published its Q1 2026 quarterly earnings report on May 8, 2026.
BioAge Labs Earnings release: Q1 2026
BioAge Labs released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
BioAge Labs reports results for Phase 1 trial of BGE-102, to initiate Phase 2
BioAge Labs (BIOA) reported results from the Phase 1 clinical trial of BGE-102, a novel, orally available, brain-penetrant small molecule NLRP3 inhibitor. The full dataset, which includes a newly anno...
BioAge Labs Transcript: Study result
Phase I results for BGE-102 showed up to 86% CRP reduction and strong safety in obese subjects, with most patients reaching CRP below 2 mg/L. The drug demonstrated potent inhibition of IL-1β and IL-6, strong CNS/ocular penetration, and supports advancement into phase II cardiovascular and ophthalmology trials.
BioAge Labs Press release: Study result
BioAge Labs issued a press release on April 21, 2026, disclosing material business information to investors.
BioAge Labs Proxy statement: Proxy filing
BioAge Labs filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
BioAge Labs Proxy statement: Proxy filing
BioAge Labs filed a proxy statement on April 21, 2026, providing details for shareholder voting and corporate governance matters.
BioAge Labs Slides: Corporate presentation
BioAge Labs has posted slides in relation to its latest quarterly earnings report, which was published on April 20, 2026.
BioAge Labs Transcript: 25th Annual Needham Virtual Healthcare Conference
The company is advancing BGE-102, a novel NLRP3 inhibitor, into phase I and II trials for cardiovascular and ophthalmology indications, with promising early efficacy and safety data. Strong financials and sector interest support a robust pipeline, including APJ agonists for obesity.
BioAge Labs initiated with a Buy at Needham
Needham initiated coverage of BioAge Labs (BIOA) with a Buy rating and $50 price target The firm is “bullish” on the company’s lead asset BGE-102, an oral, NLRP3 inhibitor in…
BioAge Labs files automatic mixed securities shelf
16:23 EDT BioAge Labs (BIOA) files automatic mixed securities shelf
BioAge Labs Annual report: Q4 2025
BioAge Labs has published its Q4 2025 annual report on March 24, 2026.
BioAge Labs Earnings release: Q4 2025
BioAge Labs released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.
BioAge Labs Slides: Corporate presentation
BioAge Labs has posted slides in relation to its latest quarterly earnings report, which was published on March 24, 2026.
BioAge Labs price target raised to $52 from $15 at Citi
Citi raised the firm’s price target on BioAge Labs (BIOA) to $52 from $15 and keeps a Buy rating on the shares. The firm sees a “compelling” outlook for the…
BioAge Labs Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The company presented strong phase I data for its oral NLRP3 inhibitor, showing best-in-class CRP reduction and favorable safety in obese patients. Key upcoming milestones include full phase I data, a three-month monotherapy trial, and a DME proof-of-concept study, with additional programs in obesity and ongoing pharma collaborations.
BioAge Labs initiated with an Outperform at Oppenheimer
Oppenheimer initiated coverage of BioAge Labs (BIOA) with an Outperform rating and $60 price target. The firm is optimistic on the company’s lead asset BGE-102’s NLRP3 inhibition. The “highly validate...
BioAge Labs upgraded to Buy from Hold at Jefferies
Jefferies analyst Roger Song upgraded BioAge Labs (BIOA) to Buy from Hold with a price target of $62, up from $9. The firm, which updated its thesis on BGE-102 and…
BioAge Labs price target raised to $23 from $12 at Morgan Stanley
Morgan Stanley raised the firm’s price target on BioAge Labs (BIOA) to $23 from $12 and keeps an Equal Weight rating on the shares. Early Phase 1 BGE-102 data indicate…